Search

Recurrent pregnancy lost (RPL) is a common condition that causes great impact on partners leading frustration, anxiety, depression, excessive spending and even breaks in the relationship. Its etiology is multifactorial and often cannot be determined. This paper describes a case of a patient who after six RPL losses, in the seventh pregnancy is detected high positive antiphospholipid antibodies. She receive thromboprophylaxis twice a week until 32 weeks of gestational age, produced a healthy preterm newborn with a good prognosis. We discuss difficulties in the diagnostic accuracy and treatment modalities described. [ABSTRACT FROM AUTHOR]

The antiphospolipid syndrome (APS) is an autoimmune disease characterized by recurrent fetal loss, thrombotic events (arterial or venous) and hemocytopenic disorders associated to high titers of circulating aPL Two variants of the APS have been described. Primary APS is a clinical entity without evidence of any other autoimmune disease and secondary APS is a clinical disorder mainly associated with Systemic Lupus Erithematosus (SLE). aPL are a widely group of immunoglobulins directed against different components or proteins factors. In 1990 three groups of researchers identified that β2GP-I is the mainly antigenic target of aPL in APS patients. There are evidences that show that more than one pathogenic mechanism is involved in the development of the APS. The best documented clinical manifestations associated with the APS are recurrent fetal loss and thrombotic disorders. The latter is based on observations in vivo in animal models and in vitro on the effects caused by β2GP-I antibodies from patients with APS or from animals which cause experimental APS. The objective of the present paper is to show the pathogenic mechanisms that participate in the development of the APS. We also presented evidence that shows that β2GP-I induces pro-inflammatory, pro-adhesive and pro-coagulant disorder. [ABSTRACT FROM AUTHOR]